近日，北京中医药大学东直门医院王勇教授和广州中医药大学王伟教授团队在Medicine Plus上发表综述文章“Anthracycline-induced cardiotoxicity: emerging mechanisms and ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

CNS Pharmaceuticals (CNSP) announced the primary analysis of its clinical trial evaluating Berubicin, the first anthracycline demonstrated to ...

Fintel reports that on March 25, 2025, Maxim Group upgraded their outlook for Moleculin Biotech (NasdaqCM:MBRX) from Hold to ...

Q4 2024 Earnings Call Transcript March 24, 2025 Operator: Hello, and welcome to the Moleculin Biotech Fourth Quarter and Full ...

The safety profile continues to be favorable, including the absence of anthracycline related cardiotoxicity. Analysis of outcomes are ongoing, including advanced imaging review, PK, and clinical ...

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.The safety pro ...

CNS Pharmaceuticals (NASDAQ: CNSP) announced results from its Phase 2 clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma ...

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...

The significant drop in CNS Pharmaceuticals’ stock price reflects investor concerns over the commercial viability of Berubicin following these trial results. The company’s next steps will likely be ...